The rare disease diagnostic odyssey, by the numbers

“Rare” is a misleading word. Individually, each rare disease affects few people, but collectively they are common. There are more than 10,000 known rare diseases, and roughly 1 in 10 Americans (over 30 million people) lives with one. Fewer than 5% have an FDA-approved treatment (NORD).

For most of those patients, getting a diagnosis is not a moment but a journey. Clinicians call it the diagnostic odyssey, and it is as costly as it is common.

How long is the wait?

Studies of rare disease patients consistently find a delay measured in years. A large European patient survey (EURORDIS Rare Barometer) found the average time from first symptoms to a correct diagnosis was several years, and a substantial share of patients waited far longer (Rare Barometer study, Orphanet Journal of Rare Diseases). Along the way, patients frequently:

• consult multiple specialists across different institutions,
• receive one or more incorrect diagnoses before the right one, and
• undergo repeated, often duplicated, testing.

Misdiagnosis is especially costly: when an incorrect diagnosis is given, the time to the correct answer can stretch dramatically longer than when it is not.

Why it takes so long

The delay is rarely due to a single missing test. More often it is structural:

• Most rare diseases are genetic and present early. An analysis of the Orphanet database estimated that about 72% of rare diseases are genetic in origin and roughly 70% have pediatric onset (Nguengang Wakap et al., European Journal of Human Genetics, 2020). Symptoms can be non-specific and easily attributed to more common conditions.
• The signal is fragmented. Relevant findings are scattered across encounters, labs, and notes that no single clinician ever sees together. The problem is usually not missing data. It’s unconnected data.
• Manual review doesn’t scale. No clinician can chart-review an entire population to find the few patients who fit a rare profile.

Turning the odyssey into a path

The encouraging part: because the evidence is so often already present in a patient’s record, it can be found systematically. Applying a governed, clinician-reviewed disease definition across existing health data can surface the patients who match a rare disease profile, turning years of scattered data into a clear path toward diagnosis.

That is the premise behind PathfindEHR™: not a guess, but a reproducible, explainable route from definition to candidate patient.

Sources

1. National Organization for Rare Disorders (NORD), Rare Disease Facts and Statistics.
2. Nguengang Wakap S, et al. Estimating cumulative point prevalence of rare diseases: analysis of the Orphanet database. European Journal of Human Genetics, 2020.
3. EURORDIS Rare Barometer, Time to diagnosis and determinants of diagnostic delays of people living with a rare disease. Orphanet Journal of Rare Diseases.

This article is for general educational purposes and is not medical advice.